较高的体重指数会减弱利拉鲁肽对接受磺脲类药物治疗的2型糖尿病患者的长期糖化血红蛋白降低作用。
A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.
作者信息
Yamamoto Takeshi, Fukui Tomoyasu, Higuchi Akiko, Ohara Makoto, Hayashi Toshiyuki, Hirano Tsutomu
机构信息
The Division of Diabetology, Metabolism and Endocrinology, The Department of Internal Medicine, Showa University of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
出版信息
Diabetol Int. 2016 Apr 13;7(4):425-431. doi: 10.1007/s13340-016-0269-8. eCollection 2016 Dec.
OBJECTIVE
To identify the attenuating factor of glycated hemoglobin (HbA1c)-lowering effects of liraglutide in type 2 diabetes (T2D) patients over the long term.
METHODS
Forty-six T2D patients received liraglutide-glimepiride combination therapy. Clinical characteristics were compared between the following two subgroups: the relapse group (≥0.4 % increase in HbA1c in 48 weeks compared to 12 weeks) and non-relapse group (remaining patients). A glucagon-loading test was performed to evaluate baseline endogenous insulin secretion.
RESULTS
In the relapse group, significantly reduced HbA1c, as observed at 12 weeks, tended to increase at 24 and 48 weeks. In the non-relapse group, reduced HbA1c was maintained for 48 weeks. Body weight was decreased at 12 weeks and then recovered at 48 weeks in both groups. Baseline BMI was significantly higher in the relapse group than in the non-relapse group. Age, HbA1c, duration of diabetes, fasting C-peptide, daily glimepiride dose and the duration of glimepiride treatment were comparable between both groups. Multiple logistic regression analysis revealed that baseline BMI was independently associated with the relapse group.
CONCLUSION
A higher BMI is the leading factor for attenuating long-term glycemic control by liraglutide in T2D patients undergoing sulfonylurea-based therapy.
目的
确定利拉鲁肽在2型糖尿病（T2D）患者中长期降低糖化血红蛋白（HbA1c）效果的减弱因素。
方法
46例T2D患者接受利拉鲁肽 - 格列美脲联合治疗。比较以下两个亚组的临床特征：复发组（与12周相比，48周时HbA1c增加≥0.4%）和非复发组（其余患者）。进行胰高血糖素负荷试验以评估基线内源性胰岛素分泌。
结果
在复发组中，12周时观察到的显著降低的HbA1c在24周和48周时趋于升高。在非复发组中，HbA1c降低维持了48周。两组体重在12周时均下降，然后在48周时恢复。复发组的基线BMI显著高于非复发组。两组之间的年龄、HbA1c、糖尿病病程、空腹C肽、每日格列美脲剂量和格列美脲治疗时间相当。多因素逻辑回归分析显示，基线BMI与复发组独立相关。
结论
较高的BMI是接受磺脲类药物治疗的T2D患者中利拉鲁肽长期血糖控制减弱的主要因素。
Zotero 插件